Cita APA

Navarro Mendivil, A., Yang, J. C. H., Ardizzoni, A., Simonelli, M., Santoro, A., Felip Font, E., & Su, W. (2022). Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer.

Citación estilo Chicago

Navarro Mendivil, Alejandro, James C. H. Yang, Andrea Ardizzoni, Matteo Simonelli, Armando Santoro, Enriqueta Felip Font, y Wu-Chou Su. Phase Ib/II Study of Ceritinib in Combination With Ribociclib in Patients With ALK-rearranged Non–small Cell Lung Cancer. 2022.

Cita MLA

Navarro Mendivil, Alejandro, et al. Phase Ib/II Study of Ceritinib in Combination With Ribociclib in Patients With ALK-rearranged Non–small Cell Lung Cancer. 2022.